CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis

Dungu, Jason; Valencia, Oswaldo; Pinney, Jennifer H.; Gibbs, Simon; Rowczenio, Dorota; Gilbertson, Janet A.; Lachmann, HJ; Wechalekar, Ashutosh; Gillmore, Julian D.; Whelan, Carol; Hawkins, Philip N.; Anderson, Lisa

doi:10.1016/j.jcmg.2013.08.015

Cited by 281 publications

(222 citation statements)

References 24 publications

Supporting

Mentioning

191

Contrasting

Unclassified

Order By: Relevance

“…To quantify myocardial accumulation of 18 F-florbetaben, both 18 Fflorbetaben retention index (RI) and percentage myocardial 18 Fflorbetaben retention were calculated. 18 F-florbetaben RI was calculated as the mean myocardial 18 F-florbetaben SUV between 15 and 20 min after injection divided by the integral of the arterial time-activity curve between 0 and 17.5 min after injection, the midpoint of 15-20 min (8).…”

Section: Cardiac Pet Analysesmentioning

confidence: 99%

“…18 F-florbetaben RI was calculated as the mean myocardial 18 F-florbetaben SUV between 15 and 20 min after injection divided by the integral of the arterial time-activity curve between 0 and 17.5 min after injection, the midpoint of 15-20 min (8). Calculation of percentage myocardial 18 F-florbetaben retention was based on the change in SUV mean on summed-framed images of the LV myocardium between 0 and 5 min and 15 and 20 min after radiotracer injection using the following formula:…”

Section: Cardiac Pet Analysesmentioning

confidence: 99%

“…where SUV 0-5 is mean myocardial SUV between 0 and 5 min and SUV [15][16][17][18][19][20] is mean myocardial SUV between 15 and 20 min.…”

Section: Cardiac Pet Analysesmentioning

confidence: 99%

“…PET imaging with 18 F-labeled florbetaben has been shown to accurately detect b-amyloid neuritic plaques in the brain in patients with Alzheimer disease (3). This agent specifically binds to the amyloid b-pleated-sheet structure (4).…”

mentioning

confidence: 99%

“…Finally, the agent may also permit quantification and monitoring of the burden of amyloid plaque deposition. Therefore, the aims of the present study were to determine the feasibility of 18 F-flobetaben PET imaging in diagnosing cardiac amyloidosis compared with a control group of patients with hypertensive heart disease and to correlate the extent of 18 F-florbetaben myocardial retention with biventricular myocardial dysfunction on 2D speckle-tracking echocardiography.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Cardiac Amyloid Imaging with ¹⁸F-Florbetaben PET: A Pilot Study

et al. 2016

View full text Add to dashboard Cite

Our aim was to determine the feasibility of 18 F-florbetaben PET in diagnosing cardiac amyloidosis. Methods: 18 F-florbetaben PET was performed on 14 patients: 5 amyloid light chain, 5 amyloid transthyretin, and 4 control with hypertensive heart disease. Qualitative and quantitative assessments of 18 F-florbetaben activity were performed using the SUV mean of the left ventricular myocardium and blood pool and calculation of target-to-background SUV ratio. Myocardial 18 F-forbetaben retention was also calculated as the percentage mean myocardial SUV change between 0 and 5 min and 15 and 20 min after radiotracer injection. Global left ventricular longitudinal and right ventricular free wall longitudinal strain were calculated using 2-dimensional speckle-tracking echocardiography. Results: Targetto-background SUV ratio and percentage myocardial 18 F-forbetaben retention were higher in amyloid patients than in hypertensive controls. A cutoff of 40% was able to differentiate between cardiac amyloid patients and hypertensive controls. Percentage myocardial 18 F-forbetaben retention was an independent determinant of both global left ventricular longitudinal and right ventricular free wall longitudinal strain via an inverse curve relationship. Conclusion: 18 F-florbetaben PET imaging can accurately identify and differentiate between cardiac amyloidosis and hypertensive heart disease. Percentage myocardial 18 F-florbetaben retention was an independent determinant of myocardial dysfunction in cardiac amyloidosis.

show abstract

Section: Cardiac Pet Analysesmentioning

confidence: 99%

Section: Cardiac Pet Analysesmentioning

confidence: 99%

“…where SUV 0-5 is mean myocardial SUV between 0 and 5 min and SUV [15][16][17][18][19][20] is mean myocardial SUV between 15 and 20 min.…”

Section: Cardiac Pet Analysesmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Cardiac Amyloid Imaging with ¹⁸F-Florbetaben PET: A Pilot Study

et al. 2016

View full text Add to dashboard Cite

show abstract

Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging

et al. 2016

View full text Add to dashboard Cite

In this multicenter study, Tc 99m PYP cardiac imaging conferred a high level of sensitivity and specificity for differentiation of patients with ATTR cardiac amyloidosis (irrespective of genotype) from patients with AL cardiac amyloidosis and patients with nonamyloid heart failure with preserved ejection fraction. An H/CL ratio of 1.6 or greater was associated with worse survival among patients with ATTR cardiac amyloidosis. Among patients for whom there is a high clinical suspicion of cardiac amyloidosis, Tc 99m PYP may be of diagnostic and prognostic importance.

show abstract